Multiple Myeloma and Chronic Lymphocytic Leukemia: From Molecular Biology to Immunology to Therapy
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: closed (31 March 2021) | Viewed by 4984
Special Issue Editors
Interests: multiple myeloma; tumor immunology; T cell response; immunotherapy; chronic lymphocytic leukemia; monoclonal gammopaty; amyloidosis; CAR-T
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Multiple myeloma (MM) and chronic lymphocytic leukaemia (CLL) are both B-cell malignancies, which arise from the clonal expansion of progenitor cells at different stages of B-cell maturity. Clinically, MM and CLL share common features, such as stage‐dependent anaemia, immune deficiency, and late stage unresponsiveness to therapy; indeed, despite the recent introduction of new drugs, both are still incurable. Additionally, both diseases are considered microenvironment-dependent malignancies, in which neoplastic B cells co-evolve together with a supportive tissue microenvironment, leading to chronic inflammation and severe impairment of immune effectors. Specific genomic alterations, such as del17p, identify high-risk patients, which could benefit from specific treatments, while other molecular markers are currently under evaluation.
This Special Issue “Multiple Myeloma and Chronic Lymphocytic Leukemia: from molecular biology to immunology to therapy” of the International Journal of Molecular Sciences, has the objective to develop an updated biological and clinical view on how molecular and immunological alterations impact pathogenesis, disease evolution from asymptomatic early stage disease, therapeutic response and clinical outcome. We welcome original basic, translational and molecular biology-based clinical research articles as well as review articles leading to improvement of the understanding of both MM and CLL disease.
Dr. Cirino Botta
Dr. Massimo Gentile
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multiple myeloma
- chronic lymphocytic leukemia
- P53
- translational medicine
- personalized treatment
- target therapy
- immuno-oncology
- biomarkers
- genetic alteration
- diagnostics and therapeutics
- molecular biology
